| Session 1. Special Speech |
|
| Chair : Soo-Ki KIM, Director, Institute of Basic Medical Science, Yonsei Univ. |
 |
- Hepatitis C Virus
: Challenge and Advancement of Viral Vaccine Development |
| Jang H. HAN, Director, HVC Vaccine Research, Novartis |
|
   |
|
|
| Session 2. Core Elements and Current Status of Cancer Vaccine |
|
| Cancer vaccine is no longer a dream but a reality. This advance has been in debt to the revolutionary discovery of core technologies in tumor immunology. In that context, fashioning cancer vaccine is more simplified. However, cancer vaccine has been diversified and tailorized in real application. This session will cover core elements and current status of cancer vaccine. Specifically, immunologic adjuvant and antigen discovery is essential requirement for powerful cancer vaccine. In parallel, we'll touch the cutting-edge application of cancer vaccine in clinic. |
| Chair : Soo Ki KIM, Professor, Institute of Basic Medical Science, Yonsei Univ. |
|
| - Discovery of Tumor Antigen for Cancer Immunotherapy |
| Sang Yull LEE, Associate Professor, Dept. of Biochemistry, College of Medicine, Pusan Univ. |
|
 |
|
- Cell-based Radioimmunotherapy and Chemoimmunotherapy for
Treatment of Human Cancer |
| Chi-Duk KANG, Professor, Pusan Univ. School of Medicine |
|
|
|
| - Immunologic Adjuvant for Cancer Vaccine & Ganglioside Antigen Cancer Vaccine |
| Soo-Ki KIM, Director, Institute of Basic Medical Sciences, Yonsei Univ. |
|
|
|
|
| Session 3. New Trend of Vaccine Development |
|
| As the main entry of most environment pathogens, mucosal surfaces such as respiratory, gastro-intestinal, and genital tracts as the first line of defense against pathogenic antigens such as AIDS, influenza virus, salmonella, shigella, TB, cholera, and HPV. Therefore, vaccination targeting mucosal tissues capable of effectively inducing both mucosal (secretory IgA Ab) and systemic immune responses (IgG Ab), thereby resulting in two layers of host protection. We would like to introduce new concept of mucosal delivery routes and current status of development of mucosal adjuvants in this session. |
Chair : Mi-Na KWEON, Chief, Mucosal Immunology Section, Int'l Vaccine Institute |
|
- Commercialization Based on Scientific Excellence
: HPV Vaccine & Others |
| Walter STRAUS, Executive Director, Scientific Affairs, Merck Vaccine Division, Merck & Co., Inc. |
|
 |
|
- Mucosal Adjuvant Activity of Flagellin, the TLR5 Agonist
: Flagellin, a New Mucosal Vaccine Adjuvant |
| Joon Haeng RHEE, Professor, Dept.of Microbiology, Chonnam Nat'l Univ. Medical College |
|
|
|
- The Sublingual Mucosa: An Efficient Delivery Route for
Inducing Protective Immune Responses
-
: Efficacy of Sublingual Mucosa |
| Mi-Na KWEON, Chief, Mucosal Immunology Section, Int'l Vaccine Institute |
|
|
|
|
|
